Release Date: February 11, 2026
Expiration Date: April 30, 2026
Activity Overview
This educational activity is an archive of the live presentation held from January 23, 2026, to January 25, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is intended for oncologists involved in the treatment and management of patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, fellows, and other health care professionals interested in the treatment of lung cancer may also participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply current evidence-based, guideline-recommended approaches to biomarker testing to inform treatment selection in patients with lung cancer
- Evaluate efficacy and safety data from recent clinical trials on established and emerging therapeutic approaches for lung cancer
- Integrate the latest clinical evidence and guideline recommendations into the development of personalized treatment plans for patients with lung cancer
- Implement best practices to identify, prevent, and manage treatment-related adverse effects associated with novel therapies for lung cancer
Julie R. Brahmer, MD, MSc, FASCO
Director, Thoracic Oncology Program
Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Director, Kimmel Cancer Center at Johns Hopkins Bayview
Baltimore, MD
Edgardo S. Santos Castillero, MD, FACP, FASCO
Medical Director, Broward County, Florida
The Oncology Institute of Hope & Innovation
Clinical Associate Professor
Charles E. Schmidt College of Medicine
Florida Atlantic University
Vice President, Florida Society of Clinical Oncology
President, FLASCO Foundation
Fort Lauderdale, FL
Mark A. Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
AdventHealth Cancer Institute
Orlando, FL
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here